文献速递肿瘤 PET/CT放射性药物与辐射防护

99mTc-替尔曼诺塞普用于乳腺癌前哨淋巴结活检的多中心真实世界研究

Sentinel Lymph Node Biopsy in Breast Cancer with 99mTc-Tilmanocept: A Multicenter Study on Real-Life Use of a Novel Tracer.
PubMed 文献 · J Nucl Med · 2020-10-09

本研究纳入344例T1-T4、N0-N2乳腺癌患者(352个病灶),评估99mTc-替尔曼诺塞普前哨淋巴结活检的表现。淋巴显像至少检出1枚前哨淋巴结的比例为96.3%,术中检出率达97.2%;正常体重患者淋巴显像检出率高于超重或肥胖患者(99.2% vs 94.6%,P=0.031),浅表注射效果优于深部注射。

要点

  • 99mTc-替尔曼诺塞普在异质性乳腺癌人群中淋巴显像检出率96.3%、术中检出率97.2%。
  • 正常体重患者淋巴显像检出率高于超重或肥胖患者(99.2% vs 94.6%,P=0.031)。
  • 浅表注射较深部注射提高术前淋巴显像和术中前哨淋巴结检出,再注射率更低(P<0.001)。

核心结论

  • 无论采用何种方案,99mTc-替尔曼诺塞普在异质性乳腺癌人群中均显示良好结果,浅表注射时效果最佳。

研究设计与样本

  • 多中心研究,纳入9个中心的344例T1-T4、N0-N2乳腺癌患者(352个病灶),采用浅表或深部注射99mTc-替尔曼诺塞普行前哨淋巴结活检。

主要发现

  • 淋巴显像至少检出1枚前哨淋巴结的比例为96.3%(339/352个病灶),术中前哨淋巴结检出率为97.2%。
  • 单因素分析显示前哨淋巴结检出率不受年龄、临床T或N分期、肿瘤位置、组织学亚型或既往新辅助治疗影响。
  • 正常体重(BMI<25)患者淋巴显像检出率高于超重或肥胖(BMI≥25)患者,分别为99.2%和94.6%(P=0.031)。
  • 浅表注射较深部注射提高术前淋巴显像检出和术中切除前哨淋巴结的比例,首次选择浅表注射时再注射病例显著减少(P<0.001)。
  • 80例前哨淋巴结活检发现阳性淋巴结,平均随访19个月期间未观察到腋窝复发。

关键数值与推荐

  • 前哨淋巴结活检阳性80例,平均随访19个月无腋窝复发。
  • 正常体重与超重或肥胖患者淋巴显像检出率分别为99.2%和94.6%(P=0.031)。

临床怎么用

  • 在乳腺癌前哨淋巴结活检中可优先考虑浅表注射99mTc-替尔曼诺塞普以提高检出率并减少再注射。
  • 对超重或肥胖患者应关注淋巴显像检出率可能较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

99mTc-tilmanocept is a novel radiopharmaceutical for sentinel lymph node (SLN) biopsy in breast cancer. Our aim was to describe results with 99mTc-tilmanocept in a heterogeneous group of breast cancer patients scheduled for SLN biopsy. Methods: Radiotracer preparation followed the manufacturer's indications. Local protocols for SLN detection within 9 participant centers were not changed for the entire duration of the study. In total, 344 patients with T1-T4, N0-N2 breast cancer (352 lesions) were included. Superficial (intradermal or periareolar) or deep (peritumoral or intratumoral) injections were performed. The doses were adjusted depending on the scheduled time for surgery. Results: Lymphoscintigraphy was able to depict at least 1 SLN in 339 of 352 breast lesions (96.3%), and the intraoperative SLN detection rate reached 97.2%. On univariable analysis, SLN detection rates did not differ by age, clinical T or N stage, tumor location, histologic subtype, or prior neoadjuvant therapy. Lymphoscintigraphy showed higher SLN detection in patients with a normal weight (body mass index < 25) than in those who were overweight or obese (body mass index ≥ 25), at 99.2% versus 94.6%, respectively (P = 0.031). The proportion of patients with preoperative lymphoscintigraphic detection or excised SLNs was higher with superficial than deep injections. Reinjected cases were significantly lower when superficial injection was chosen first (P < 0.001). Injection site and the tumor markers human epidermal growth factor receptor 2 and estrogen receptor had an impact on preoperative SLN visualization and intraoperative localization. In 80 cases, SLN biopsy resulted in a positive lymph node. During a mean follow-up of 19 mo, no axillary recurrences were observed. Conclusion: Whatever the protocol, 99mTc-tilmanocept showed good results in a heterogeneous breast cancer population, although the best results were achieved when a superficial injection was chosen.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Vidal-Sicart S, Rioja ME, Prieto A, et al. Sentinel Lymph Node Biopsy in Breast Cancer with 99mTc-Tilmanocept: A Multicenter Study on Real-Life Use of a Novel Tracer. J Nucl Med. 2020. PMID: 33037087. doi:10.2967/jnumed.120.252064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。